Patrys Limited announced data from its completed preclinical study which has demonstrated that Patrys' full-sized deoxymab antibody, PAT-DX3, can be used as a targeting agent for antibody drug conjugates (ADC) to deliver anti-cancer drugs to tumours. Patrys previously announced in September 2021 preliminary data showing that administration of an ADC in which PAT-DX3 was conjugated to the anticancer drug monomethyl auristatin E (MMAE) significantly inhibited the growth of tumours in mice implanted with xenografts of the human breast cancer cell line MCF7. With this study now complete, Patrys reports that this inhibition of tumour growth resulted in a significant improvement in survival in animals treated with the ADC based on Patrys' PAT-DX3 deoxymab. At day 60, the completion date for this study, 80% of the animals treated with PAT-DX3-MMAE were still alive (red). This was 39 days after the last treatment with PAT-DX3-MMAE was administered. By comparison, all of the animals in the untreated control group had been euthanised because of tumour growth by day 60 (black), and only one animal treated in the non-specific, control antibody group remained alive (blue). PAT-DX3-MMAE significantly increased survival compared to the control group of animals (p<0.005). In this study, PAT-DX3-MMAE was administered to mice (6 mice per group) on days 0, 7, 14 and 21 of the study (shown as arrows in the figure above). The control groups comprised animals that received no treatment as well animals that were treated with a non-specific antibody conjugated to MMAE.